SNY Sanofi SA: Market Capitalization to Book Value Ratio

Sanofi relies on the premium status of Dupixent, although EU regulators are capping the cost of legacy drugs. Analyzing the market cap to book value ratio chart in GURU.Markets, where the metric value is 1.29, an investor can see the market valuation of assets. The behemoth is combating biosimilars through biotech acquisitions, investing billions into immunology to protect its market share from patent cliffs.

Sanofi (SNY) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

SNY (Sanofi SA): analytical breakdowns and indicator data

- price and consensus price forecast:

Price Chart Sanofi|SNY - Forecast Levels Chart

- market capitalization data:

Market Capitalization Sanofi Aventis|SNY - Value Adjusted for Debt and Cash

- book capitalization data:

Book Value per Share Sanofi|SNY - Book Capitalization|Market Value to Book Value Ratio sanofi.com|SNY - Aggregate Asset Value

- debt and liquidity data:

Debt to Equity Sanofi|SNY - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Sanofi Aventis|SNY - Company Aggregate Debts|Debt to Book Value Sanofi Aventis

Basic company analysis:SNY (Sanofi)

This ratio measures the market value premium over net assets, reflecting investor confidence in future cash flows relative to book value. In the context of Sanofi (SNY), the current market-to-book value ratio on GURU.Markets demonstrates how the market values intellectual capital and mRNA expertise amid structural workforce optimization, determining the resilience of the company's fundamental valuation.

Competitor analysis